Johnson & Johnson (J&J) has announced that its investigational intravesical gemcitabine releasing system has been accepted ...

The National Institute for Health and Care Excellence (NICE) has recommended BeOne Medicines’ targeted cancer drug Brukinsa ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Impetus Digital was promoted to the Aclymate Silver Tier for their efforts in crafting carbon-neutral virtual and live ...

Novartis’ Kisqali (ribociclib) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved KalVista Pharmaceuticals’ Ekterly (sebetralstat) ...

GCI Health has announced a realignment of its European leadership team, with Annalise Coady being appointed as president of Europe and Kath Harrison assuming the newly created position of president of ...

Leading global healthcare services provider, Uniphar, has launched Uniphar | Global Sourcing, a new identity for its On Demand business that strengthens its position as a strategic sourcing partner ...

Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.

The European Commission (EC) has approved BeOne Medicines’ Tevimbra (tislelizumab) as part of a first-line combination ...

Pfizer and Astellas Pharma have shared positive top-line results from a late-stage study of their androgen receptor signalling inhibitor Xtandi (enzalutamide) in a subset of prostate cancer patients.